Based NSW

Dr Andrew Parsonson is an early career medical oncologist affiliated with the Nepean Cancer Care Centre in Sydney, Australia. He was the inaugural advanced trainee representative on the Clinical Oncology Society of Australia (COSA) council and has a strong interest in the education and professional development of trainees and young oncologists. His current research interests are in the role of digital health in cancer care and clinical trials and he has recently commenced a part-time PhD through the Australian Institute of Health Innovation (AIHI) at Macquarie University. He has recently been appointed to be a member on the drug utilisation subcommittee (DUSC) to provide advice on oncology drug utilisation to the Pharmaceutical Benefits Advisory Committee (PBAC).

Based in QLD

Dr Mark Nalder is a Medical Oncologist and early career researcher. He is currently the Medical Oncology Fellow at Royal Brisbane and Women’s Hospital, QLD. He has strong clinical interests in thoracic, gastrointestinal, genitourinary and melanoma malignancies. His research interests include precision medicine, pharmacogenetics and the utilisation of real-world evidence to guide treatment decisions for patients with cancer. He is currently completing a PhD at the University of Queensland, investigating the real-world outcomes of patients treated with immunotherapy. He is passionate about reducing treatment related toxicity and is the principal investigator on a multi-site trial of prospective DPYD genotype guided dosing for patients receiving fluoropyrimidine chemotherapy.

Based in WA

Dr Tim Slattery is an early career medical oncologist, currently working at Fiona Stanley Hospital and Geraldton Regional Hospital. He completed his training across Fiona Stanley Hospital and Sir Charles Gairdner Hospital in Western Australia, as well as the Royal Marsden NHS Foundation Trust in London, United Kingdom. His interests include genitourinary, colorectal, lung and skin cancers, as well rural & regional cancer care, and exercise & well-being in cancer. He also has a passion for education, career equity, advocacy & mentorship, and is involved in various related service improvement programs. He is currently working across many solid tumour clinical trials, including the active development of a phase 1 trial looking at the addition of chemotherapy to radionuclide therapy for the treatment of prostate cancer.

Tim is also a qualified general & acute care physician with significant regional experience, having received RACP fellowship in 2020.

Dr Connolly is an early career medical oncologist and clinician researcher who is affiliated with Chris O Brien Lifehouse (COBLH), the Children’s Medical Research Institute (CMRI) and the University of Sydney. She is currently undertaking full time PhD research in sarcoma proteomics after completing a sarcoma clinical research fellowship at COBLH. Her interests include sarcoma, rare cancers and AYA care. She is passionate about education and professional development of trainees and young oncologists. She is a current member of the European Society of Medical Oncology (ESMO) Young Oncologists Committee (YOC) and has been an inaugural member of the NSW/ACT Medical Oncology Advanced Trainee Committee (MOAT) and several Royal College of Physicians (RACP) education committees. Through these she has facilitated the development of a number of physician education resources and programmes.

Dr James McCracken is a Medical Oncologist, with expertise in the management and care of patients with breast, lung and gastrointestinal (oesophagus, stomach, pancreas, bowel and liver) cancers.

Dr McCracken is a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre & Epworth Freemasons. He is currently undertaking a MPhil through the University of Melbourne, investigating clinical, genomic and transcriptomic landscape of HER2-low breast cancer, supervised by Prof Sherene Loi & Prof Sarah-Jane Dawson.

Dr McCracken graduated from the Australian National University in 2011, graduating with the Australian Medical Association Leadership Prize in his final year. He then went on to complete Basic Physicians Training through the Royal Melbourne Hospital. During this time, he also concurrently completed a Master’s in Public Health, through the University of Sydney.

Dr McCracken did his Medical Oncology training through the Victorian Medical Oncology Training Programme, at St Vincent's, Northern, Western and Austin Hospitals, before completing a 2 year fellowship in Breast and Gastrointestinal Oncology at the Olivia Newton-John Cancer Research Institute at the Austin Hospital. He is also a member of the Medical Oncology Group of Australia, the European Society of Medical Oncology, and the American Society of Clinical Oncology.

In his spare time, he enjoys time with his wife Laura and children, Hamish and Hattie. He’s also a keen cyclist, amateur chef and sommelier and one-eyed Hawthorn fan.

Dr Meagan Inglis is an early-career Medical Oncologist who is currently completing a Clinical Research Fellowship at Western Health, Victoria. She studied undergraduate Medicine at the University of Melbourne prior to completing her Basic Physician Training at Ballarat and Western Health. She subsequently completed her advanced training across Western Victoria at Bendigo Health, Barwon Health, Western Health and the Peter MacCallum Cancer Centres. Meagan’s clinical interests are in Gynae and GI cancers, and she is a volunteer speaker for the Counterpart Organisation, providing training at their Peer Support Training Program on the role of systemic treatment in the management of cancers. Meagan has a passion for medical administration, and is also undertaking a Master of Health Leadership and Management/Master of Public Health at UNSW. In her free time, Meagan enjoys spending time with her young family keeping her toddler entertained at the various Zoos across Victoria.

Dr O'Neil is a Medical Oncologist located in Perth, WA and is currently dual-training in cancer genetics at the Genetic Services of WA with the aim of working in investigation and treatment of rare cancers and in the care of patients with hereditary cancer predisposition syndromes.